Growth • Verve Therapeutics
VERV
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
0%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
0%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
0%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
0%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
0%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!